PIK3R1 Protein (p85α - Phosphoinositide-3-Kinase Regulatory Subunit 1)
Introduction PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1), commonly known as p85α, is the major regulatory subunit of class IA phosphoinositide 3-kinases (PI3Ks). This critical signaling protein plays essential roles in cellular growth, survival, metabolism, and synaptic function. Dysregulation of p85α and PI3K/Akt signaling is strongly implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and stroke. This page provides comprehensive information about p85α structure, function, and its involvement in neurodegeneration.
<div class="infobox .infobox-protein"> | | | |---|---| | Protein Name | Phosphoinositide-3-Kinase Regulatory Subunit 1 (p85α) | | Gene Symbol | [PIK3R1](/genes/pik3r1) | | UniProt ID | [P27986](https://www.uniprot.org/uniprot/P27986) | | Molecular Weight | 85 kDa | | Amino Acids | 724 | | Subcellular Localization | Cytoplasm, plasma membrane, endosomes | | Protein Family | PI3K regulatory subunit (p85) family | | Brain Expression | [Cortex](/brain-regions/cortex), [Hippocampus](/brain-regions/hippocampus), Cerebellum, Basal ganglia | | PDB Structure | [4A0B](https://www.ebi.ac.uk/pdbe/entry/pdb/4A0B), [4JPS](https://www.ebi.ac.uk/pdbe/entry/pdb/4JPS), [4OVU](https://www.ebi.ac.uk/pdbe/entry/pdb/4OVU) | </div>
Overview ...
PIK3R1 Protein (p85α - Phosphoinositide-3-Kinase Regulatory Subunit 1)
Introduction PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1), commonly known as p85α, is the major regulatory subunit of class IA phosphoinositide 3-kinases (PI3Ks). This critical signaling protein plays essential roles in cellular growth, survival, metabolism, and synaptic function. Dysregulation of p85α and PI3K/Akt signaling is strongly implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and stroke. This page provides comprehensive information about p85α structure, function, and its involvement in neurodegeneration.
<div class="infobox .infobox-protein"> | | | |---|---| | Protein Name | Phosphoinositide-3-Kinase Regulatory Subunit 1 (p85α) | | Gene Symbol | [PIK3R1](/genes/pik3r1) | | UniProt ID | [P27986](https://www.uniprot.org/uniprot/P27986) | | Molecular Weight | 85 kDa | | Amino Acids | 724 | | Subcellular Localization | Cytoplasm, plasma membrane, endosomes | | Protein Family | PI3K regulatory subunit (p85) family | | Brain Expression | [Cortex](/brain-regions/cortex), [Hippocampus](/brain-regions/hippocampus), Cerebellum, Basal ganglia | | PDB Structure | [4A0B](https://www.ebi.ac.uk/pdbe/entry/pdb/4A0B), [4JPS](https://www.ebi.ac.uk/pdbe/entry/pdb/4JPS), [4OVU](https://www.ebi.ac.uk/pdbe/entry/pdb/4OVU) | </div>
Overview p85α is encoded by the PIK3R1 gene and serves as the principal regulatory subunit of class IA PI3Ks. The protein regulates the catalytic p110 subunit (p110α, p110β, p110δ) by controlling its localization, stability, and enzymatic activity. p85α contains multiple protein-protein interaction domains that allow it to couple activated cell surface receptors to intracellular signaling cascades[@yu1998].
Protein Structure
Domain Architecture p85α (724 amino acids) contains several distinct domains:
N-terminal SH3 domain (1-85): Binds proline-rich sequences via PXXP motifs
Bcr homology domain (85-300): Contains the inter-SH2 (iSH2) region critical for p110 binding
iSH2 domain (300-500): Forms the main interface with p110 catalytic subunit
C-terminal SH2 domain (cSH2) (600-620): Binds phosphotyrosine motifs on activated receptors
N-terminal SH2 domain (nSH2) (330-420): Regulates p110 activity
Structural Features
Molecular weight : ~85 kDa
Isoforms : p85α, p55α (pik3r1 splice variant), p50α
Post-translational modifications : Phosphorylation (Y459, Y467), ubiquitination
Normal Function
PI3K Activation and Regulation p85α is essential for PI3K function:
Receptor recruitment : SH2 domains bind phosphorylated tyrosine residues on activated RTKs (e.g., insulin receptor, EGFR, PDGFR)
p110 recruitment : iSH2 domain brings the p110 catalytic subunit to the membrane
Autoinhibition release : p85α relieves p110 autoinhibition, enabling PIP2 phosphorylation
PIP3 production : p110 converts PIP2 to PIP3, a key second messenger
Signaling Pathways
PI3K/Akt pathway : Major downstream effector of p85α-regulated PI3K
[mTOR](/entities/mtor) pathway : Akt activates mTORC1 for protein synthesis
[GSK-3β](/entities/gsk3-beta) regulation : Akt phosphorylates and inhibits GSK-3β
FOXO transcription factors : Akt phosphorylates FOXO, promoting its cytoplasmic retention
Cellular Processes
Cell survival : Akt-mediated inhibition of pro-apoptotic proteins (Bad, caspase-9)
Metabolism : Insulin signaling, GLUT4 translocation, lipid synthesis
Protein synthesis : mTORC1 activation
Cell growth : Ribosome biogenesis and translation
Synaptic plasticity : [NMDA](/entities/nmda-receptor) receptor trafficking, AMPA receptor insertion
Brain Functions
Neuronal survival : Neurotrophic factor signaling (BDNF, NGF)
Synaptic plasticity : [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and memory formation
Metabolic regulation : Neuronal glucose uptake
Axonal guidance : Growth cone dynamics
Role in Neurodegeneration
Alzheimer's Disease p85α and PI3K signaling are prominently affected in AD:
Reduced p85α expression : Decreased levels in AD hippocampus and cortex
Impaired Akt signaling : Downstream of p85α, Akt activity is reduced
[Tau](/proteins/tau) pathology : PI3K/Akt normally inhibits GSK-3β; loss promotes [tau](/proteins/tau) hyperphosphorylation
Amyloid-beta effects : [Aβ](/proteins/amyloid-beta) disrupts insulin-PI3K-Akt signaling
Synaptic failure : PI3K is critical for synaptic plasticity; dysfunction contributes to memory deficits
Neuronal survival : Reduced neuroprotection against Aβ toxicity
Parkinson's Disease
Dopaminergic neuron survival : PI3K/Akt is critical for nigral neuron survival
LRRK2 interactions : Pathogenic LRRK2 affects PI3K pathway signaling
[α-Synuclein](/proteins/alpha-synuclein) pathology : PI3K/Akt dysfunction may sensitize [neurons](/entities/neurons) to α-synuclein toxicity
Neurotrophic factors : GDNF signaling relies on PI3K/Akt
Amyotrophic Lateral Sclerosis (ALS)
Motor neuron survival : PI3K/Akt pathway promotes motor neuron viability
Glutamate excitotoxicity : PI3K signaling can counteract excitotoxic cell death
Mitochondrial function : PI3K helps maintain mitochondrial health
Stroke and Ischemia
Ischemic preconditioning : PI3K/Akt activation is neuroprotective
Reperfusion injury : PI3K signaling can reduce oxidative damage
Angiogenesis : PI3K promotes blood vessel formation post-stroke
Type 2 diabetes link : p85α mutations/dysfunction may increase AD risk
Insulin resistance : [Brain insulin signaling](/entities/brain-insulin-signaling) impairment in both T2D and AD
Therapeutic Implications
PI3K/Akt Pathway Modulators | Drug/Compound | Target | Development Stage | Potential Use | |---------------|--------|-------------------|---------------| | Wortmannin | PI3K (irreversible) | Research tool | Lab studies | | LY294002 | PI3K (reversible) | Research tool | Lab studies | | Idelalisib | p110δ | Approved (oncology) | Under investigation | | Alpelisib | p110α | Approved (oncology) | May benefit brain | | Metformin | AMPK activation | Approved (diabetes) | Under investigation for AD |
Challenges
Broad pathway effects : Systemic PI3K inhibition causes metabolic dysfunction
[Blood-brain barrier](/entities/blood-brain-barrier) : Drug delivery to CNS is challenging
Biphasic effects : Constitutive activation can be oncogenic
Therapeutic Strategies
p85α modulators : Developing compounds that enhance p85α function
Akt activators : Direct Akt activation bypasses p85 dysfunction
Neurotrophic factors : BDNF mimetics that activate PI3K
Therapeutic Implications
PI3K/Akt Pathway Modulators | Drug/Compound | Target | Development Stage | Potential Use | |---------------|--------|-------------------|---------------| | Wortmannin | PI3K (irreversible) | Research tool | Lab studies | | LY294002 | PI3K (reversible) | Research tool | Lab studies | | Idelalisib | p110δ | Approved (oncology) | Under investigation | | Alpelisib | p110α | Approved (oncology) | May benefit brain | | Metformin | AMPK activation | Approved (diabetes) | Under investigation for AD |
Challenges
Broad pathway effects : Systemic PI3K inhibition causes metabolic dysfunction
Blood-brain barrier : Drug delivery to CNS is challenging
Biphasic effects : Constitutive activation can be oncogenic
Therapeutic Strategies
p85α modulators : Developing compounds that enhance p85α function
Akt activators : Direct Akt activation bypasses p85 dysfunction
Neurotrophic factors : BDNF mimetics that activate PI3K
Role in ALS
Motor neuron survival : PI3K/Akt pathway promotes motor neuron viability
Glutamate excitotoxicity : PI3K signaling can counteract excitotoxic cell death
Mitochondrial function : PI3K helps maintain mitochondrial health
Role in Stroke and Ischemia
Ischemic preconditioning : PI3K/Akt activation is neuroprotective
Reperfusion injury : PI3K signaling can reduce oxidative damage
Angiogenesis : PI3K promotes blood vessel formation post-stroke
Cross-Links
[PIK3R1 Gene](/genes/pik3r1)
[PIK3CA Protein (p110α)](/proteins/pik3ca-protein)
[PI3K-AKT Pathway](/mechanisms/pi3k-akt-pathway)
[mTOR Pathway](/mechanisms/mtor-pathway)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[GSK-3β Mechanisms](/mechanisms/gsk-3-beta)
[Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)
See Also
[Akt Protein (AKT1)](/proteins/akt1-protein)
[mTOR Protein](/proteins/mtor-protein)
[IRS Proteins](/entities/irs-proteins)
[PDK1 Protein](/proteins/pdk1-protein)
[PTEN Protein](/proteins/pten-protein) — negative regulator
References
[Cantley LC, The phosphoinositide 3-kinase pathway (2002)](https://pubmed.ncbi.nlm.nih.gov/11967143/)
[Hers I, Tavare JM, PI3K in neuronal cells (2011)](https://pubmed.ncbi.nlm.nih.gov/21418177/)
[Zhang H, Chen X, Liu Y, et al, PI3K/Akt dysfunction in Alzheimer's disease (2022)](https://doi.org/10.1007/s12035-021-02635-8)
[Bassil F, Brown PJ, Lothian J, et al, PI3K signaling in Parkinson's disease (2021)](https://doi.org/10.1007/s10571-020-01021-8)
[Baek JH, Lee K, Kim S, et al, p85α deficiency in neurons (2020)](https://pubmed.ncbi.nlm.nih.gov/33060155/)
[Liu Y, Wang X, Chen Q, et al, PI3K/Akt in stroke neuroprotection (2019)](https://doi.org/10.1007/s11064-019-02824-0)
[Moloney AM, Griffin RG, Timmons S, et al, Defects in IGF-1 and PI3K signaling in Alzheimer's disease (2010)](https://doi.org/10.3233/JAD-2010-090794)
Show full description